Alerta

DETECTION OF CHANGES IN PATIENT HEALTH BASED ON GLUCOSE DATA

Resumen de: US20260000322A1

This disclosure is directed to systems and techniques for detecting change in patient health based upon patient data. In one example, a medical system comprising processing circuitry communicably coupled to a glucose sensor and configured to generate continuous glucose sensor measurements of a patient. The processing circuitry is further configured to: extract at least one feature from the continuous glucose sensor measurements over at least one time period, wherein the at least one feature comprises one or more of an amount of time within a pre-determined glucose level range, a number of hypoglycemia events, a number of hyperglycemia events, or one or more statistical metrics corresponding to the continuous glucose sensor measurements; apply a machine learning model to the at least one extracted feature to produce data indicative of a risk of a cardiovascular event; and generate output data based on the risk of the cardiovascular event.

SAFETY TOOLS FOR DECISION SUPPORT RECOMMENDATIONS MADE TO USERS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS

Resumen de: US20260000323A1

Systems and method are described for determining if a decision support recommendation is to be presented to a user for treatment of a diabetic state, including receiving a plurality of input data items impacting a diabetic state of a user of continuous glucose monitor, the input data items serving as input data to a process for determining a decision support recommendation; assigning a reliability level to each of the input data items; calculating a reliability metric based on the reliability levels assigned to each of the input data items; determining a decision support recommendation based on the process and the input data and presenting the decision support recommendation to the user on a user interface only if the reliability metric exceeds a threshold.

DATA VISUALIZATION FOR CONTINUOUS GLUCOSE MONITORING

Resumen de: US20260000321A1

A method for continuous glucose monitoring includes a processor of a computing device operatively coupled to or integrated with a display receiving data. The data includes a plurality of glucose levels, and each glucose level of the plurality of glucose levels is associated with a corresponding time. The processor processes the data to generate a first graphical element indicative of a current glucose level, and one or more second graphical elements indicative of a rate and a direction of change of the glucose level. The processor via a graphical user interface displays the first graphical element on the display and the one or more second graphical elements on the display. The one or more second graphical elements are positioned relative to the first graphical element to visually indicate whether the glucose level is stable, increasing, or decreasing.

DIABETIC FOOT HEALING SYSTEM AND METHOD

Resumen de: US20260000154A1

The present invention is a diabetic healing system for the treatment of diabetic foot ulcers. This device promotes the healing process of diabetic foot ulcers by completely offloading the pressures that an ulcer may be subjected to regardless of its size, shape or location on the foot/ankle and/or toes. The device is made of a custom rigid outer shell and a custom inner lattice structure that fully supports, stabilizes and conforms to all aspects of a patient's condition, anomalies and disfigurement. It completely offloads (zero contact) any ulceration regardless of the location on the foot, ankle or toes. The offloading occurs through the use of recessed areas that can be incorporated directly into the lattice structure, or can be included in a “plug” that fits within a small aperture in the lattice structure.

MEDICAMENT DELIVERY DEVICE WITH AN ADJUSTABLE AND PIECEWISE ANALYTE LEVEL COST COMPONENT TO ADDRESS PERSISTENT POSITIVE ANALYTE LEVEL EXCURSIONS

Resumen de: US20260004910A1

The exemplary embodiments may modify a glucose cost component of the cost function of the control loop of an insulin delivery device to compensate for persistent positive low level glucose excursions relative to a target glucose level. The exemplary embodiments may enable use of different glucose cost component functions for different glucose levels of the user. These glucose cost component functions may be employed in piecewise fashion with a different piece being applied for each respective range of glucose level values for the user. The final glucose cost function for calculating the glucose cost component may be a weighted combination of a piecewise glucose cost function and a weighted standard cost function (such as a quadratic function). The weights may reflect the magnitude and/or persistence of glucose excursions relative to a target glucose level.

DATA BACKFILLING FOR CONTINUOUS GLUCOSE MONITORING

Resumen de: US20260004927A1

Methods and apparatus, including computer program products, are provided for backfilling. In some example embodiments, there is provided a method that includes receiving, at a receiver, backfill data representative of sensor data stored, at a continuous blood glucose sensor and transmitter assembly, due to a loss of a wireless link between the receiver and the continuous blood glucose sensor and transmitter assembly; generating, at the receiver, at least one of a notification or a graphically distinct indicator for presentation at a display of the receiver, the at least one of the notification or the graphically distinct indicator enabling the backfill data to be graphically distinguished, when presented at the display, from non-backfill data; and generating, at the receiver, a view including the backfill data, the non-backfill data, and the generated at least one of the notification or the graphically distinct indicator. Related systems, methods, and articles of manufacture are described.

BIOELECTRONICS BASED ON FUNCTIONALIZED PROTEINS

Resumen de: EP4671378A1

The invention relates to chemical, electrochemical and non-covalently bioconjugation (functionalization) of proteins with catalytic properties. A functionalization method is disclosed using all organic solvents except dimethylformamide (DMF), and dimethyl sulfoxide (DMSO), and utilizing organic synthesis and non-covalent insertion methods. Furthermore, the invention encompasses the preparation of bioelectrodes designed for the detection of substances, including but not limited to glucose, lactose, galactose (as carbohydrates), dopamine, adrenaline (epinephrine), noradrenaline (norepinephrine), and serotonin (as neurotransmitters), L-glutamate, D- or L-amino acids, hydrogen peroxide, nicotine, cholesterol, ethanol, oxalate, lactate, and pyruvate in food products, as well as in human body fluids serving as real samples. Additionally, this invention extends to the utilization of bioelectrodes for monitoring chemical processes, including features and the chemical environment of neuron interfaces within the brain. The invention encompasses an electrochemical inhibitor testing system utilizing the aforementioned bioelectrodes, and the functionalized proteins as single-molecular protein-based memristors.

SYSTEM FOR REGULATING THE CONCENTRATION OF GLUCOSE IN THE BLOOD OF A PERSON

Resumen de: WO2024175639A1

The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying at least one and preferably two substances to said person, - at least one and preferably two infusion sets connectable to said device; - at least one sensor for measuring a glucose concentration in the blood of said person; - a controller for controlling said device such that a certain amount of a said substance is supplied per time unit, wherein said controller is arranged to determine a slope of the measured glucose concentration and if said slope exceeds a first threshold value said controller is arranged to control the device to supply a pre-injection amount of said at least one substance, said pre-injection amount being a percentage of a maximum pre-injection amount, wherein said percentage is dependent on the determined slope.

CLOSED LOOP CONTROL OF PHYSIOLOGICAL GLUCOSE

Resumen de: EP4671882A2

The present disclosure relates to a system for closed loop control of glycemia. In one arrangement, the system comprises: an insulin delivery device; a user interface for inputting patient data, the patient data including a basal insulin profile, an insulin-to-carbohydrate ratio, and meal data; and a controller in communication with the user interface and the insulin delivery device and configured to receive glucose data. The controller is further configured to execute: estimating an amount of active insulin in the patient, the active insulin not including the basal insulin profile, determining a meal carbohydrate value from the meal data, estimating a physiological glucose for the patient and a rate of change of physiological glucose based in part on the glucose data, determining an attenuation factor based on the physiological glucose and the rate of change of the physiological glucose, determining a meal bolus based on meal data, the insulin-to-carbohydrate ratio, and the determined attenuation factor, modifying the determined meal bolus based on the estimated amount of active insulin in the patient, and transmitting a request to deliver the modified meal bolus to the insulin delivery device.

SYSTEM FOR REGULATING THE CONCENTRATION OF GLUCOSE IN THE BLOOD OF A PERSON

Resumen de: WO2024175636A1

The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying at least one and preferably two substances, - at least one and preferably two infusion sets connectable to said device for infusing a said substance to said person; - at least one sensor for measuring a glucose concentration in the blood of said person; - a controller for controlling said device such that a certain amount of a said substance is supplied per time unit and thereby infused into the body of the person via said or a respective infusion set, wherein said certain amount is chosen in accordance with the measured glucose concentration, wherein said controller is arranged to determine a slope of the measured glucose concentration, and wherein the time unit per which the certain amount is supplied is dependent on said slope.

SYSTEM FOR REGULATING THE CONCENTRATION OF GLUCOSE IN THE BLOOD OF A PERSON

Resumen de: WO2024179895A1

The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying insulin and glucagon, - at least two infusion sets; - at least one sensor for measuring a glucose concentration in the blood of said person, and - a controller for controlling said device such that a certain amount of insulin and glucagon is supplied per time unit, wherein said certain amount is chosen in accordance with the measured glucose concentration as prescribed by an insulin injection curve and a glucagon injection curve, wherein said controller is further arranged to determine if glucagon is supplied to said person in a chosen time frame, and wherein the controller is arranged to re-assess and optionally adjust the insulin injection curve based on the determination if glucagon is supplied to said person in said chosen time frame.

SYSTEM, METHOD, AND COMPUTER READABLE MEDIUM FOR ADAPTIVE BIO-BEHAVIORAL CONTROL (ABC) IN DIABETES

Resumen de: WO2024178261A1

A method, system, and computer readable medium for implementing the Adaptive Bio-Behavioral Control concept, which allows for bi-directional, human-machine co-regulation of metabolic disorders, such as diabetes mellitus. The Adaptive Bio-Behavioral Control concept may encompass, but is not limited thereto, three modules: a) a Physiological Adaptation Module which processes a user's historical data to estimate a personalized model of the user's glucose metabolism and to calculate suggested insulin-dosing parameters; b) a Behavioral Adaptation Module which assists the user's adaptation to the treatment action by determining a plurality of actionable information and risk assessments based on the user's glucose monitoring records; and c) a Replay Module which computes a simulation of effects from hypothetical changes to the user's treatment or behavior based on a personalized model of the user's glucose metabolism.

ANTI-PLASMA KALLIKREIN ANTIBODY FORMULATIONS

Resumen de: WO2025264901A1

Disclosed herein are formulations of antibodies directed against plasma kallikrein, e.g., anti-plasma kallikrein antibodies. The formulations include, for example, amino acids, sugars, and surfactants. The disclosed formulations are useful for administration to subjects to treat plasma kallikrein associated disorders such as hereditary angioedema (HAE).

COMPUTER IMPLEMENTED METHOD FOR DETECTING AN OPERATION STATUS OF AN ANALYTE SENSOR FOR CONTINUOUS ANALYTE MONITORING, COMPUTER SYSTEM, COMPUTER PROGRAM PRODUCT, AND CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: WO2025261683A1

The present disclosure refers to a computer implemented method for detecting an operation status of an analyte sensor (10) for continuous monitoring an analyte, comprising: receiving continuous monitoring data for an analyte detected by an analyte sensor (10); detecting a loss of sensitivity for the analyte sensor (10), comprising determining a sensitivity indicator indicative of a sensor sensitivity of the analyte sensor (10) from the continuous monitoring data, providing a critical measure for the sensitivity indicator, and determining the loss of sensitivity for the analyte sensor (10), if the sensitivity indicator matches the critical measure for the sensitivity indicator; and detecting a defect status for the analyte sensor (10), comprising receiving an impedance value indicative of an impedance measured for the analyte sensor (10), providing a critical measure for the impedance of the analyte sensor (10), and determining the defect status for the analyte sensor (10), if the impedance value matches the critical measure for the impedance of the analyte sensor (10). A failure of the analyte sensor (10) is detected if for the analyte sensor (10) at least one of the loss of sensitivity and the defect status is determined, and, in response to detecting the failure of the analyte sensor (10), at least one of providing failure data indicative of the failure of the analyte sensor (10) and deactivating the analyte sensor (10) is conducted. Further, a computer system, a computer p

DYNAMIC MEASUREMENT OF CONSTITUENT CONCENTRATION IN AQUEOUS SOLUTIONS

Resumen de: US2025387548A1

Constituents of a liquid, such as blood, may exhibit optical signatures that allow for real-time, dynamic concentration detection. For example, concentrations of substances in aqueous solutions, including calcium, potassium, sodium, bicarbonate, chloride, magnesium, phosphate, lactate, acetate, glucose, creatinine, urea, and/or hydrogen peroxide, may be monitored during dialysis or other treatments. This is achieved by measuring real-time changes in light intensity at wavelengths corresponding to the constituents' optical signatures. Concentration may be determined using a predetermined relationship between light intensity and concentration at isolated wavelengths. Real-time monitoring enables timely treatment adjustments, improving patient outcomes.

PREVENTING YELLOWING AND FLUORESCENCE IN EPOXIDE DIAMINE NETWORKS

Resumen de: US2025387054A1

An encasement material that resists degradation, including yellowing. The encasement material may be used, for example, in an apparatus including a housing, circuitry at least partially within the housing, that is implanted into an animal (e.g. a human) to continuously monitor the concentrations of specific analytes, such as glucose. The encasement material allows for the efficient transmission of excitation and emission light to and from an analyte indicator in the device. The encasement material includes additives that resist and inhibit degradation of the encasement material thereby improving the longevity and life of the device. Also, methods for forming the encasement material and incorporating the encasement material within an apparatus.

An Extended Duration Infusion System

Resumen de: US2025387564A1

An extended duration infusion set/system suitable for transcutaneous delivery of a treatment fluid to a subject is described. The infusion set reduces and delays fibrotic capsule formation on and around an infusion cannula, and increases the effective lifetime of an infusion set significantly. The infusion set comprises a deflectable therapy reservoir to “actively” diffuse insulin and negate the effects of the foreign body response (FBR).

DISPLAY FOR PUMP

Resumen de: US2025391384A1

An apparatus comprising a pump configured to deliver insulin, a processor, and a user interface including a color display. Color on the display can be used to bring a user's attention to a change in status of the device or a detected change in status of the patent.

TUBE CONNECTOR FOR AN INFUSION SET

Resumen de: US2025387561A1

The present disclosure relates to a tube connector (402) for an infusion set, for example for delivering insulin from an insulin pump. The tube connector includes a connector body (404) adapted for connection with a tube (406). The tube connector also includes opposing first and second latch arms (412, 414) resiliently joined to the connector body at flexing points (420, 422). The tube connector also includes a first lever (424) attached to the first latch arm and a second lever (426) attached to the second latch arm. The first and second levers extend alongside the first and second latch arms, respectively, such that pressing the first and second levers towards each other deflects the first and second latch arms relative to the body portion about the flexing points.

NEEDLE RETRACTION ASSEMBLY FOR A DEVICE FOR DELIVERING INSULIN

Resumen de: WO2024173658A2

An infusion system comprising: a device configured to deliver medication to a user through an infusion catheter, wherein the device includes a housing configured to receive the infusion catheter and to maintain the infusion catheter in the user after insertion; and a detachable activation mechanism for deploying the device for delivering medication to the user, wherein the detachable activation mechanism comprises a trigger and a retraction mechanism that includes an introducer needle for introducing the infusion catheter into the user, wherein the detachable activation mechanism is configured to releasably connect to the housing, wherein the detachable activation mechanism is configured to insert the infusion catheter into the user, automatically release the detachable activation mechanism from the housing responsive to activation of the trigger and automatically retract the introducer needle into the needle retraction assembly to shield the needle upon the automatic release of the detachable activation mechanism.

MANUAL INSULIN PUMP CONFIGURATION

Resumen de: WO2025259242A1

The invention relates to a manually controlled manual insulin pump configuration suitable for use by diabetic individuals who have to inject with an insulin pen before each meal or high blood sugar correction dose.

METHOD OF DISPLAYING COMMUNICATION STATUS IN GLUCOSE MONITORING SYSTEM

Resumen de: US2025380912A1

One embodiment may provide a method of displaying a communication status in a glucose monitoring system, the method including displaying a communication status of a communication module in a terminal configured to transmit and receive data with a sensor transmitter, when the communication module is turned off, delaying a display of a communication module turn-off for one period of time by the terminal, and if the turn-off of the communication module persists for the one period of time, displaying the communication module turn-off.

OPTICAL SHORT-WAVE INFRARED SENSOR FOR BIOMEDICAL APPLICATIONS

Resumen de: WO2025258837A1

The present invention relates to an optical sensor and a wearable device comprising the same for non-invasively determining a concentration of blood components, for example, blood glucose and glycated hemoglobin levels. The optical sensor comprises an emitter configured to emit short-wave infrared (SWIR) radiation, an insulator with a channel transparent to the SWIR radiation, the emitter being disposed on top of the insulator and configured to emit the radiation into a biological tissue through the transparent channel, an optical concentrator made from a material with a refractive index of 1.7 or more, and a photodetector disposed in an upper part of the optical concentrator. The invention provides the possibility of non-invasive, instant or continuously monitoring of blood glucose and glycated hemoglobin levels. 2 indep. claims and 13 dep. claims, 15 figs., 2 tables.

METHOD OF OUTPUTTNG BLOOD GLUCOSE DATA

Resumen de: AU2025202475A1

One embodiment may provide a method of outputting blood glucose data including obtaining biometric information in response to an advertisement transmitted by a sensor transmitter, generating the biometric information as output, in the case that a communication failure occurs, indicating a data gap during a period of the communication failure, and if the communication failure is resolved, filling the data gap during a period from a time point when the communication failure is resolved to one advertisement which arrives after the communication failure is resolved. One embodiment may provide a method of outputting blood glucose data including obtaining biometric information in response to an advertisement transmitted by a sensor transmitter, generating the biometric information as output, in the case that a communication failure occurs, indicating a data gap during a period of the communication failure, and if the communication failure is resolved, filling the data gap during a period from a time point when the communication failure is resolved to one advertisement which arrives after the communication failure is resolved. pr p r c o m m u n i c a t i o n f a i l u r e i s r e s o l v e d @ pr p r

METHOD OF PROVIDING NOTIFICATION OF SIGNAL LOSS IN GLUCOSE MONITORING SYSTEM

Nº publicación: AU2025201860A1 18/12/2025

Solicitante:

I SENS INC
i-SENS, INC

Resumen de: AU2025201860A1

One embodiment may provide a method of providing a notification of signal loss in a glucose monitoring system, the method including, when a communication failure occurs between a terminal and a sensor transmitter, delaying a signal loss notification for a first period of time by the terminal, when the communication failure persists for the first period of time, further determining whether signal loss persists for a second period of time by the terminal, when the signal loss persists for the second period of time, generating the signal loss notification by the terminal, and outputting, by the terminal, the signal loss notification to a user. One embodiment may provide a method of providing a notification of signal loss in a glucose monitoring system, the method including, when a communication failure occurs between a terminal and a sensor transmitter, delaying a signal loss notification for a first period of time by the terminal, when the communication failure persists for the first period of time, further determining whether signal loss persists for a second period of time by the terminal, when the signal loss persists for the second period of time, generating the signal loss notification by the terminal, and outputting, by the terminal, the signal loss notification to a user.20 ar a r t o a u s e r Sensor module Sensor communicator Sensor controller Sensor storage 120 130 140 Outputter Communicator Controller Storage 220 230 240 ar a r